MURRAY, FRANK & SAILER LLP is investigating securities fraud claims against Medivation, Inc. ("Medivation" or the "Company") (NASDAQ:MDVN) and certain of its officers and directors, on behalf of purchasers of Medivation securities between July 17, 2008 and March 2, 2010, inclusive (the "Class Period").
It is alleged that during the Class Period, defendants violated federal securities laws by failing to disclose important negative information concerning the efficacy of the Company's drug Dimebon as a treatment for Alzheimer's disease, and the prospects for FDA approval to market Dimebon.
On March 3, 2010, before the market opened, defendants were forced to publicly disclose that Dimebon did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer's disease. As a result of this news, Medivation's stock plummeted $27.15 per share, or 67%, to close at $13.10 on volume of 45 million shares.
If you purchased Medivation securities within the Class Period, you may move the Court, not later than May 10, 2010, to serve as Lead Plaintiff for the class. A Lead Plaintiff is a representative chosen by the Court who acts on behalf of other class members in directing the litigation. You do not need to be a Lead Plaintiff to be included in the class. If you wish to discuss this litigation, or have any questions concerning this notice or your rights or interests with respect to these matters, please contact us.
Contact:
MURRAY, FRANK & SAILER LLP
Eva Hromadkova
212-682-1818
800-497-8076
